LUGANO, Schweiz–(BUSINESS WIRE)–Dr. Roberto Pinelli, CEO des Switzerland Eye Research Institute, meldete heute die Veröffentlichung einer bahnbrechenden Abhandlung in den Archives Italiennes de Biologie, einer der ältesten Fachzeitschriften zum Thema…
Author: Business Wire
Le Switzerland Eye Research Institute a publié une étude de cas révolutionnaire utilisant l'exposition à la lumière et les nutraceutiques pour traiter la dégénérescence rétinienne.
LUGANO, Suisse–(BUSINESS WIRE)–Le Dr Roberto Pinelli, CEO du Switzerland Eye Research Institute, a annoncé aujourd’hui la publication d’un article révolutionnaire dans les Archives italiennes de biologie, l’une des plus anciennes revues de neuroscien…
The Switzerland Eye Research Institute Published a Breakthrough Case Report Using Light Exposure and Nutraceuticals for Treating Retinal Degeneration
LUGANO, Switzerland–(BUSINESS WIRE)– #NEUROSCIENCE–A breaktrough treatment using light through photobiomodulation and nutraceuticals is effective for the treatment of retinal degeneration.
New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc announced results from an analysis showing treatment with UPLIZNA effectively reduced the severity of attacks in NMOSD.
Alcon Reports Fourth Quarter and Full Year 2021 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Fourth Quarter and Full Year 2021 Results
Alcon Reports Fourth Quarter and Full Year 2021 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Fourth Quarter and Full Year 2021 Results
H2 2021 Global Glaucoma Clinical Trials Review – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This report provides an overview of Glaucoma Clinical trials scenario. This report provides top line …
PatientFi Closes $15 Million Equity Round
IRVINE, Calif.–(BUSINESS WIRE)–PatientFi®, an emerging leader in patient financing, today announced the completion of a $15 million investment round. The round was led by Patriot Financial Partners with participation from Curql Collective, through Cu…
New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced results from a post-marketing safety analysis of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease.
Global Macular Edema Clinical Trials Market Report, H2 2021 Edition – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Macular Edema – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. The report provides an overview of Macular Edema Clinical trials scenario. This report provides …
Global Optical Preclinical Imaging Market (2021 to 2030) – by Modality, End-user and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Preclinical Imaging Market by Modality and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering. The global optical preclinical imaging …
Harrow Health to Present at Aegis Virtual Conference
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will present a company over…
Ranibizumab Biosimilars Market Research 2022: Comprehensive Insights About 17+ Companies and 17+ Marketed and Pipeline Drugs – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ranibizumab biosimilars – Insight, 2022” report has been added to ResearchAndMarkets.com’s offering. The publisher’s, “Ranibizumab Biosimilars – Pipeline Insight, 2022,” report provides comprehensive insights about 17+ com…
Global Intraocular Lens Market Segment Forecasts 2022-2030, Featuring Alcon, Bausch & Lomb, Rayner, Lenstec and STAAR Surgical Company – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Intraocular Lens Market Size, Share & Trends Analysis Report by Product (Multifocal Intraocular Lens, Toric Intraocular Lens), by End Use (Hospitals, Ambulatory Surgery Centers), by Region, and Segment Forecasts, 2022-…
Mandy Moore與Lumenis合作，提高對乾眼症和OptiLight療法的認識
以色列約克尼姆伊利特–(BUSINESS WIRE)–(美國商業資訊)–Lumenis今天宣布已與唱作人兼演員Mandy Moore合作，由Mandy Moore擔任乾眼症理想解決方案OptiLight的品牌大使。Moore女士患有乾眼症，OptiLight療法使她的病情得到明顯改善。現在她與Lumenis合作，分享她的故事，並激勵其他人。她將在OptiLight的新廣告中演出，告訴數以百萬計的乾眼症患者，不必「默默忍受」。 在確診之前，Moore女士沒有意識到眼睛乾燥、瘙癢、灼熱感實際上是乾…
Mandy Moore与Lumenis合作，提高对干眼症和OptiLight疗法的认识
以色列约克尼姆伊利特–(BUSINESS WIRE)–(美国商业资讯)–Lumenis今天宣布已与唱作人兼演员Mandy Moore合作，由Mandy Moore担任干眼症理想解决方案OptiLight的品牌大使。Moore女士患有干眼症，OptiLight疗法使她的病情得到明显改善。现在她与Lumenis合作，分享她的故事，并激励其他人。她将出演OptiLight的新广告，告诉数以百万计的干眼症患者，不必“默默忍受”。 在确诊之前，Moore女士没有意识到眼睛干燥、瘙痒、灼热感实际上是干眼症…
Iveric Bio annonce l’achèvement de l’analyse post-hoc de l’anatomie fovéale de l’essai clinique GATHER1 évaluant le Zimura® chez des patients atteints d’atrophie géographique
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) a annoncé aujourd’hui l’achèvement de l’analyse post-hoc visant à évaluer divers paramètres de croissance de l’atrophie géographique (AG) afin d’étudier le taux de progression de la maladie dan…
Resumen: Iveric Bio anuncia el análisis post hoc de la anatomía foveal del ensayo clínico GATHER1 de Zimura® en pacientes con atrofia geográfica
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) ha anunciado hoy un análisis post hoc en el que se han evaluado varios parámetros de crecimiento de la atrofia geográfica (AG) para explorar la tasa de progresión de la enfermedad en varias reg…
Samenvatting: Iveric Bio kondigt Foveal Anatomy Post-Hoc-analyse aan van GATHER1 Clinical Trial of Zimura® bij patiënten met geografische atrofie
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) heeft vandaag een post-hocanalyse aangekondigd waarin verschillende groeiparameters voor geografische atrofie (GA) werden geëvalueerd om de snelheid van ziekteprogressie in verschillende regio’…
Riassunto: Iveric Bio annuncia un'analisi post-hoc dell'anatomia foveale dallo studio clinico GATHER1 su Zimura® nei pazienti con atrofia geografica
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) oggi ha annunciato un’analisi post-hoc che ha valutato diversi parametri di crescita dell’atrofia geografica (AG) per esplorare il tasso di progressione della malattia, in varie regioni della f…